Navigation Links
Diabetes Drug Avandia Boosts Heart Risks: Study

Another study finds a similar drug, Actos, may be a better choice, researchers say

TUESDAY, Sept. 11 (HealthDay News) -- A controversial drug called Avandia, used by millions of diabetics to control blood sugar, greatly increases their risk of heart attack and heart failure, researchers report.

The drug does not up users' overall risk of death, however, the new study finds.

"The balance of risks and benefits has shifted, and this needs to be factored into the equation," said Dr. Sonal Singh, lead author of the study and assistant professor of internal medicine at Wake Forest University School of Medicine in Winston-Salem, N.C.

"The risk of heart failure was known but not the magnitude. A doubling of risk is substantial," Singh added. "One in 30 patients taking rosiglitazone (Avandia) over a year will have heart failure, that's very substantial. And one in 220 will have a heart attack. That's also very substantial." Patients should talk to their doctors about the potential risks and benefits of the drug, Singh said.

The study is published in the Sept. 12 issue of the Journal of the American Medical Association, as does another study, this one finding that Actos (pioglitazone), a diabetes drug in the same class as Avandia, actually reduces the risk of heart attack, stroke and death, even while it increases the risk for serious heart failure.

"This study shows that this drug, used for sugar control, provides an additional benefit of reducing cardiovascular complications," said Dr. A. Michael Lincoff, lead author of the study and vice chairman for research in the department of cardiovascular medicine at the Cleveland Clinic. "This is very strong reassurance."

It's unclear what the new conclusions mean for this class of drugs, called thiazolidinediones. Previous studies have indicated cardiovascular risks, and, in August, the FDA mandated stricter labeling, including "black-box" warnings, for the medications.

"The whole area of thiazolidinediones has been thrown wide open by all these meta-analyses," said Dr. Gregory Dehmer, professor of internal medicine at Texas A&M Health Science Center College of Medicine and director of the cardiology division at Scott & White Hospital in Temple. "For the average clinician in the street, there's a substantial amount of uncertainty, and this is magnified for patients," he said

For the first study, Singh and his colleagues conducted a meta-analysis of four randomized trials of Avandia involving more than 14,000 patients.

In the analysis, Avandia increased the risk of heart attack by 42 percent and doubled the risk of heart failure, similar to findings of a previous study. In this analysis, Avandia did not increase the risk of death from cardiovascular causes, however.

The study received no funding from GlaxoSmithKline, the maker of Avandia.

With an estimated 3.5 million or more U.S. patients taking Avandia, the public health impact could be substantial, the authors point out. This could translate into more than 4,000 excess heart attacks and 9,000 excess heart failure events.

For the second study, also a meta-analysis, Lincoff and his colleagues looked at data from 19 trials involving more than 16,000 participants that looked at Actos and cardiovascular complications.

According to the study authors, Actos' manufacturer, Takeda Pharma, funded the analysis and provided the data from the trials but was not involved in any of the analysis.

Like Avandia, Actos also raised users' risk for heart failure, this time by about 40 percent.

However, unlike Avandia, patients receiving Actos had an 18 percent lower risk of heart attack, stroke or death than patients in the control group.

Why might two drugs in the same class have different effects? "For this type of drug, a 'class' is a really loose term, because the medications have very different actions on multiple targets," Lincoff said. Actos should probably be the first-line choice, over Avandia, he said.

And more trials, namely randomized trials looking at specifically at cardiovascular outcomes, are needed to fully assess the effects of the drugs, Dehmer added.

More information

For more on diabetes drugs, visit the U.S. Food and Drug Administration.

SOURCES: A. Michael Lincoff, M.D., vice chairman for research, department of cardiovascular medicine, Cleveland Clinic; Sonal Singh, M.D., assistant professor of internal medicine, Wake Forest University School of Medicine, Winston-Salem, N.C.; Gregory Dehmer, M.D., professor of internal medicine, Texas A&M Health Science Center College of Medicine and director, cardiology division, Scott & White Hospital, Temple; Sept. 12, 2007, Journal of the American Medical Association

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Diabetes and Depression often go hand-in-hand
3. Vitamin E, the latest warrior against diabetes
4. Thirty minutes of work up per day reduces the risk of Diabetes
5. New Drug for Diabetes
6. Diabetes, obesity rates shooting up
7. Promising Treatment for Diabetes
8. Caffeine Found To Worsen Diabetes
9. Transplant helps diabetes
10. Dissecting Diabetes - Is protein AKT2 the cause of type 2 diabetes?
11. Higher Rates Of Diabetes Found Among The Poor
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
Breaking Medicine Technology: